Epidermal growth factor receptor (EGFR) inhibitors have been used to target non-small cell lung cancer (NSCLC) and chordomas with varying amounts of success. We have probed several key structural features including an interaction with Asp855 within the EGFR DGF motif and interactions with the active site water network. The EGFR target engagement was then evaluated in an in-cell assay. Additionally, inhibitors were profiled in representative cellular models of NSCLC and chordomas. In addition to a structure activity relationship insights for EGFR inhibtior design, we also identified a compound (18) that is the most potent inhibitor (IC50 = 310 nM) on the UCH-2 chordoma cell line to date.
Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. 1 Kinases have been successfully utilized as drug targets for the past 30 years, with 38 kinase inhibitors approved by the FDA to date for mainly cancer indications. 2 One target that has been intensely studied is epidermal growth factor receptor (EGFR). The inhibitors gefitinib and erlotinib provide significant clinical benefit in patients diagnosed with non-small cell lung cancer (NSCLC) (Fig. 1 ). [3] [4] The subsequent development of lapatinib as a dual EGFR and Her2 inhibitor has extended the clinical utility of EGFR inhibitors to the treatment of Her2 positive breast cancers ( Fig. 1 ). 5 Therapeutic intervention in the EGFR pathway is not limited to NSCLC and breast cancer. Other cancers show sensitivity to EGFR inhibitors. 6 These include chordomas, which are rare tumors arising along the bones of the central nervous system and spine. 7 These tumors are a significant challenge to treat and radical surgery is the preferred course of treatment. [7] [8] EGFR and its ligand, EGF, are highly expressed in chordomas, and copy number gains of EGFR occur in 40% of chordomas. A number of EGFR inhibitors have been identified that are active in cellular models of chordoma, and afatinib is now undergoing phase 2 clinical trials for treatment of chordoma. [9] [10] [11] [12] Kinase inhibitors commonly have off-targets across the kinome that confound the ability to accurately define the mechanism of action leading to induced phenotypes of interest. 13 The 4-anilinoquinoline and quinazolines scaffold have demonstrated a range of activity profiles across the kinome from highly selective to broadly promiscuous. [14] [15] We were intrigued by lapatinib's narrower spectrum kinome profile in addition to the longer chained aniline substituent that reduces common off-target activity by accessing a back pocket in the EGFR ATP-binding site. One significant tractable off-target is cyclin-G-associated kinase (GAK) which is frequently observed to bind 4-anilino-quinoline, quinazolines and 3-cyano-quinolines. 16 We first designed a small series of compounds to probe the hinge region to investigate the influence of the hinge binding moiety while maintaining the simple erlotinib aniline. To determine the effect of small subtle core modification, these compounds were docked into EGFR using the Schrödinger Maestro suite ( We prepared several focused arrays of compounds to probe the structure activity relationships of the quinoline/quinazoline series. We synthesized a series of compounds (1-9, 13-15, 17-19) through nucleophilic aromatic displacement of commercially available 4chloroquin(az)olines in excellent yields (58-85 %), consistent with previous reports (Sch. 1). [14] [15] 18 These compounds were profiled in an EGFR cellular activity assay, in addition to a lung cancer cell line and several chordoma cell lines (Tab. 1). The 6,7-dimethoxyquinolin-4-amine with the erlotinib 3-ethynylaniline (1) showed high potency in the in-cell EGFR phosphorylation assay (IC50 = 270 nM), as previously reported. 19 The data on the chordoma cell lines (UCH-1 and UCH-2) is also consistent with previous reports. 19 The A431 lung cancer cell line showed good activity at IC50 = 1.4 µM and threefold weaker potency on WS-1 normal fibroblast cell viability. The removal of either methoxy group to form the 6-methoxy (2) or 7methoxy (3) yielded compounds with more than a 60-fold drop in EGFR in cell potency. This also led to a drop off in cellular potency in the lung cancer cell line and UCH-1, there was a double in potency in UCH-2. However, the potency values of 2 and 3 were still in the low double digit micromolar range.
Scheme 1. General synthetic procedure
The switch to the quinazoline (4) showed a similar potency range to 1 with a slight increase in potency in A431 cells. The removal of either methoxy (5 and 6) had no impact on in cell EGFR activity but did reduce activity in all 3 cancer cell lines with no effect in WS-1. The 3-cyano quinoline hinge binder showed a marked drop off in cell EGFR activity. The 6,7-dimethoxy analog (7) showed similar potencies to the mono-methoxy quinazolines (5 and 6). It was then surprising that the removal of either methoxy (8 and 9) reduced the anti-proliferative effect seen in other analogs (7) , suggesting the involvement of other targets.
With the results of the small focused series in hand, we then started to modify the aniline scaffold, with the aim of establishing an internal hydrogen bond, not only to form a pre-organized structure but also to form an interaction with Asp855 as in Figure  3 . In tandem we looked at the water network in EGFR ( Fig. 4 ) and found that by adding a methyl group to the pendent benzyl we were able to increase the ligand efficiency of our model system. 19 We prepared several additional compounds (13) (14) (15) (16) (17) (18) where the anilines were not readily available as the ones in Scheme 1, following a three-step protocol from commercially available 2amino-5-nitrophenol (10) as starting material. 10 was coupled with CDI to furish an amide bond, followed by H2 reduction to give intermediates 11 and 12 (Sch. 2). SNAr reactions of intermediates 11 and 12 under reflux provided compounds 13-15 and 17 in good yields (58-76%). 18 The des-hydroxy compound (16) proved inaccessible via a nucleophilic aromatic displacement (even up to 150 o C, DMF, DIPEA, 18 h) and required Buchwald-Hartwig conditions (Sch. 3) to produce 16 in good overall yield (72%). 15 The 6,7-dimethoxyquinolin-4-amine with the lapatinib derived hydroxy amide aniline (13) showed double digit micromolar potency in the in-cell EGFR phosphorylation assay and moderate activity in the A431 cell line and good activity in both chordoma cell lines tested. Removal of one of the methoxy groups (14 and 15) had the opposite effect to the previous set (1-9) and led to an increase in activity in the chordoma cell lines with no change in the A431 anti-proliferative effect.
Interestingly our hypothesis of including the alcohol proved to be pivotal for activity, with the removal of the alcohol (16) removing the bulk of the activity previously observed in 13-15. We also considered increasing the bulk tert-butyl on the pendant benzyl (17) to more fully occupy the displaced water pocket. This only led to additional molecular weight with no potency gain compared with 13. It was surprising that the para-methyl benzylic ether substitution (18) with no alcohol showed no in-cell EGFR activity and a limited effect in A431 cells. However, in the two chordoma cell lines there was a sharp increase in activity. 18 is one of the most potent compounds seen to data with an IC50 of 330 nM and 310 nM for UCH-1 and UCH-2 respectively. This result is more impressive considering that UCH-2 is typically less sensitive to compound treatment. However 18 does show some observed toxicity in WS-1. The removal of the benzyl in 19 had a similar effect to removing the alcohol in 16 with most activity lost, but moderate potency in A431 was still observed.
We were also interested in the conformation of 13 to see if there would be a rigidity imparted by the alcohol onto the pendant arm structure that was not observed in 16. The small molecule crystal structure of 13 was solved as a monoclinic structure with a 27:73 to the pre-organization to the internal seven membered ring system ( Fig 5) . 20 This system would likely be more ordered, however under our crystalisation conditions the alcohol forms a 2.99Å hydrogen bond with the chloride ion. This significant electrostatic component within the lattice acts as an anchor, hindering further pre-organisation.
27
: 73 EGFR inhibitors have been used to target NSCLC and chordomas, with variation in efficacy across inhibitors and increasing resistance to inhibitors, particularly in the case of NSCLC. 21 We have highlighted a series od modifications investigating the effect of key structural features on the quin(az)oline scaffold. These modifications can be used to enhance or reduce EGFR activity and generally have a pronounced effect on cellular potency.
One of the key results observed was with the removal of one the methoxy groups from 1 leading to a significant drop off in incell EGFR and anti-proliferative effects. Interestingly this is not observed in the other quinazoline and 3-cyanoquinoline templates. This was also less significant when looking at the extended aniline structure of 13-16 where the alcohol interaction with Asp855 and conformational rigidity were more significant. It was also clear that the benzyl substitution had a significant contribution to the activity despite not been in the key hinge binding interaction. The most surprising result was compound 18, which showed limited EGFR activity but the most potent anti-proliferative effect in both UCH-1 and UCH-2 chordoma cell lines. Despite some toxicity observed in WS-1 cells, 18 could prove to be an interesting starting point for further investigations in chordomas and NSCLC and highlights the complexity of both cancer biology and target engagement. 3W2S) have been co-crystallized with at resolution of 1.9 Å with small molecule inhibitor. 23 The PDB structure of EGFR was h-bond optimized and minimized using standard protein preparation procedure of Schrödinger suite. The ligand docking was performed using SP settings of Schrodinger docking protocol with softened vdw potential (scaling 0.6), except for 7 where induced fit docking protocol was used employing standard settings. In order to improve convergence of docking poses a hydrogen bond constraint to mainchain NH of hinge residue M793 was required, as experimentally observed in the case of quinoline/quinolizine scaffolds. The grid box was centered using coordinate center of the core structure of corresponding x-ray ligand as template. Graphical illustrations were generated using, Maestro and PyMOL software of Schrödinger.
Hydration Site Analysis
Hydration site analysis calculated with WaterMap (Schrödinger Release 2018-4: WaterMap, Schrödinger, LLC, New York, NY, 2018.). The structure of EGFR (PDB:3W2S) was prepared with Protein Preparation Wizard (as above). 23 Waters were analyzed within 6 Å from the docked ligand, and the 2 nS simulation was conducted with OPLS3e force field. 18. General procedure for the synthesis of 4-anilinoquin(az)olines:
4-chloroquin(az)oline derivative (1.0 eq.), aniline derivative (1.1 eq.), and i Pr2NEt (2.5 eq.) were suspended in ethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatography using EtOAc:hexane followed by 1-5 % methanol in EtOAc; After solvent removal under reduced pressure, the product was obtained as a free following solid or recrystallized from ethanol/water.
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